Therefore, the elucidation of the molecular mechanisms that result in primary or acquired resistance to vemurafenib and sensitivity to combined MAPK and AKT/mTOR pathway inhibition, would provide useful biomarkers to rationally choose the most appropriate therapy in BRAFV600E mutant melanomas resistant to vemurafenib. The gene discussed is MTOR; the disease is melanoma.